Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Inducible silencing of protein kinase D3 inhibits secretion of tumor-promoting factors in prostate cancer.

LaValle CR, Zhang L, Xu S, Eiseman JL, Wang QJ.

Mol Cancer Ther. 2012 Jul;11(7):1389-99. doi: 10.1158/1535-7163.MCT-11-0887. Epub 2012 Apr 24.

2.

PKD2 and PKD3 promote prostate cancer cell invasion by modulating NF-κB- and HDAC1-mediated expression and activation of uPA.

Zou Z, Zeng F, Xu W, Wang C, Ke Z, Wang QJ, Deng F.

J Cell Sci. 2012 Oct 15;125(Pt 20):4800-11. doi: 10.1242/jcs.106542. Epub 2012 Jul 13.

3.

Protein kinase D3 (PKD3) contributes to prostate cancer cell growth and survival through a PKCepsilon/PKD3 pathway downstream of Akt and ERK 1/2.

Chen J, Deng F, Singh SV, Wang QJ.

Cancer Res. 2008 May 15;68(10):3844-53. doi: 10.1158/0008-5472.CAN-07-5156.

4.

[Protein kinase D3 is involved in negative regulation of MMP-7 in prostate cancer cells].

Zou ZP, Feng L, Xu WF, Ke ZY, Wang QJ, Deng F.

Nan Fang Yi Ke Da Xue Xue Bao. 2010 Aug;30(8):1767-70. Chinese.

5.

SD-208, a novel protein kinase D inhibitor, blocks prostate cancer cell proliferation and tumor growth in vivo by inducing G2/M cell cycle arrest.

Tandon M, Salamoun JM, Carder EJ, Farber E, Xu S, Deng F, Tang H, Wipf P, Wang QJ.

PLoS One. 2015 Mar 6;10(3):e0119346. doi: 10.1371/journal.pone.0119346. eCollection 2015.

6.

New pyrazolopyrimidine inhibitors of protein kinase d as potent anticancer agents for prostate cancer cells.

Tandon M, Johnson J, Li Z, Xu S, Wipf P, Wang QJ.

PLoS One. 2013 Sep 23;8(9):e75601. doi: 10.1371/journal.pone.0075601. eCollection 2013.

7.
8.

Protein kinase d as a potential chemotherapeutic target for colorectal cancer.

Wei N, Chu E, Wipf P, Schmitz JC.

Mol Cancer Ther. 2014 May;13(5):1130-41. doi: 10.1158/1535-7163.MCT-13-0880. Epub 2014 Mar 14.

9.

Protein kinases D2 and D3 are novel growth regulators in HCC1806 triple-negative breast cancer cells.

Hao Q, McKenzie R, Gan H, Tang H.

Anticancer Res. 2013 Feb;33(2):393-9.

PMID:
23393329
10.

Effective Targeting of Estrogen Receptor-Negative Breast Cancers with the Protein Kinase D Inhibitor CRT0066101.

Borges S, Perez EA, Thompson EA, Radisky DC, Geiger XJ, Storz P.

Mol Cancer Ther. 2015 Jun;14(6):1306-16. doi: 10.1158/1535-7163.MCT-14-0945. Epub 2015 Apr 7.

11.

Opposing growth regulatory roles of protein kinase D isoforms in human keratinocytes.

Ryvkin V, Rashel M, Gaddapara T, Ghazizadeh S.

J Biol Chem. 2015 Apr 24;290(17):11199-208. doi: 10.1074/jbc.M115.643742. Epub 2015 Mar 23.

12.

Elevated protein kinase D3 (PKD3) expression supports proliferation of triple-negative breast cancer cells and contributes to mTORC1-S6K1 pathway activation.

Huck B, Duss S, Hausser A, Olayioye MA.

J Biol Chem. 2014 Feb 7;289(6):3138-47. doi: 10.1074/jbc.M113.502633. Epub 2013 Dec 11.

13.

[PKD3 contributes to up-regulation of prostate-specific antigen in prostate cancer cells].

Deng F, Wang CX, Xu WF, Feng L, Ke ZY, Wang QJ, Zou ZP.

Nan Fang Yi Ke Da Xue Xue Bao. 2010 Aug;30(8):1779-82. Chinese.

14.

Small interfering RNA-directed targeting of Toll-like receptor 4 inhibits human prostate cancer cell invasion, survival, and tumorigenicity.

Hua D, Liu MY, Cheng ZD, Qin XJ, Zhang HM, Chen Y, Qin GJ, Liang G, Li JN, Han XF, Liu DX.

Mol Immunol. 2009 Sep;46(15):2876-84. doi: 10.1016/j.molimm.2009.06.016. Epub 2009 Jul 29.

PMID:
19643479
15.

Targeted knockdown of SEPT9_v1 inhibits tumor growth and angiogenesis of human prostate cancer cells concomitant with disruption of hypoxia-inducible factor-1 pathway.

Amir S, Golan M, Mabjeesh NJ.

Mol Cancer Res. 2010 May;8(5):643-52. doi: 10.1158/1541-7786.MCR-09-0497. Epub 2010 Apr 20.

16.

Aquaporin 3 promotes prostate cancer cell motility and invasion via extracellular signal-regulated kinase 1/2-mediated matrix metalloproteinase-3 secretion.

Chen J, Wang Z, Xu D, Liu Y, Gao Y.

Mol Med Rep. 2015 Apr;11(4):2882-8. doi: 10.3892/mmr.2014.3097. Epub 2014 Dec 16.

PMID:
25515250
17.

A short-hairpin RNA targeting osteopontin downregulates MMP-2 and MMP-9 expressions in prostate cancer PC-3 cells.

Liu H, Chen A, Guo F, Yuan L.

Cancer Lett. 2010 Sep 1;295(1):27-37. doi: 10.1016/j.canlet.2010.02.012. Epub 2010 Mar 6.

PMID:
20207476
18.

Silencing of CCR7 inhibits the growth, invasion and migration of prostate cancer cells induced by VEGFC.

Chi BJ, Du CL, Fu YF, Zhang YN, Wang RW.

Int J Clin Exp Pathol. 2015 Oct 1;8(10):12533-40. eCollection 2015.

19.

Protein kinase D1 inhibits cell proliferation through matrix metalloproteinase-2 and matrix metalloproteinase-9 secretion in prostate cancer.

Biswas MH, Du C, Zhang C, Straubhaar J, Languino LR, Balaji KC.

Cancer Res. 2010 Mar 1;70(5):2095-104. doi: 10.1158/0008-5472.CAN-09-4155. Epub 2010 Feb 16.

20.

Knockdown of HMGB1 inhibits growth and invasion of gastric cancer cells through the NF-κB pathway in vitro and in vivo.

Zhang J, Kou YB, Zhu JS, Chen WX, Li S.

Int J Oncol. 2014 Apr;44(4):1268-76. doi: 10.3892/ijo.2014.2285. Epub 2014 Jan 28.

PMID:
24481712

Supplemental Content

Support Center